Beacon says gene therapy succeeds in key trial of rare eye disease XLRP

Beacon Therapeutics reported Monday that its gene therapy for X-linked retinitis pigmentosa met its primary endpoint in a Phase 3 trial, according to Endpoints News. The result marks a rare success in a disease area where larger drugmakers have previously failed, including Johnson & Johnson and Biogen, both of which discontinued their own XLRP gene therapy programs after disappointing trial data.

XLRP is a rare inherited retinal disorder that causes progressive vision loss, predominantly in males, due to mutations in the RPGR gene. It has drawn sustained interest from gene therapy developers because it is a single-gene disorder affecting a defined, accessible tissue, the retina, making it a longstanding target for viral vector delivery approaches. Despite that appeal, the clinical track record in XLRP has been marked by setbacks industry-wide.

Endpoints News reports that Beacon’s positive Phase 3 data now positions the company to pursue regulatory next steps, though the report does not specify a timeline for filing or additional trial details beyond the endpoint success.

The company’s result comes as gene therapy developers more broadly continue to navigate a difficult path from early clinical promise to approved, marketed treatments, with rare eye diseases remaining one of the field’s more closely watched proving grounds.